Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced its full year results for the twelve months ended 30 June 2024.
Highlights
· New strategic approach launched in August 2024 with a focus on the development and partnering of high-value Optimer assets with licensing potential.
· Group reorganisation with a refreshed Board and cost base reduced to enable strategy delivery.
· Dr Adam Hargreaves appointed Non-Executive Chair of Aptamer Group, Dr Arron Tolley re-appointed as Chief Executive Officer, Andrew Rapson appointed as Chief Financial Officer in August 2024 and Tim Sykes appointed to the Board as Non-Executive Director in September 2024.
· Commercial pipeline rebuilt with increasing revenue momentum in the second half of the financial year and £1.0 million in orders won in the last quarter.
· Delivering on our strategic milestones, including:
· Increased commercial traction and advancing to licensing of critical reagent with a top five pharmaceutical partner.
